Anesthesia and analgesia
-
Anesthesia and analgesia · Jul 2003
Case ReportsBrugada-type electrocardiographic pattern induced by epidural bupivacaine.
In this case report, we describe the postoperative occurrence of electrocardiogram changes suggestive for the Brugada syndrome in a patient receiving a continuous epidural bupivacaine infusion. After withdrawal of bupivacaine, the electrocardiogram changes were reversible. The patient's history was unremarkable except for an incomplete right bundle branch block. We conclude that local anesthetics, particularly bupivacaine, have the potential to induce serious arrhythmias in patients with Brugada syndrome.
-
Anesthesia and analgesia · Jul 2003
Case ReportsLocal anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain.
Switching from bupivacaine to lidocaine may improve intrathecal morphine analgesia in advanced cancer patients, possibly because of different spinal mechanisms limiting the hyperalgesic processes.
-
Anesthesia and analgesia · Jul 2003
Clinical TrialThe effects of tidal volume and respiratory rate on oxygenation and respiratory mechanics during laparoscopy in morbidly obese patients.
Morbidly obese (MO) patients undergoing laparoscopy have lower PaO(2) compared with normal-weight (NW) patients. We hypothesized that increases in tidal volume (V(T)) or respiratory rate (RR) would improve oxygenation. All measurements were performed at: 1) baseline: V(T) 600-700 mL and 10 breaths/min, 2) double V(T): V(T) 1200-1400 mL and 10 breaths/min, and 3) double rate: V(T) 600-700 mL and 20 breaths/min. We calculated static respiratory system compliance (Cst,rs) and inspiratory resistance (RI,rs). End-tidal CO(2) was measured with a mass spectrometer, and PaO(2) and PaCO(2) with a continuous blood gas monitor. Supine anesthetized MO patients had 29% lower Cst,rs than the NW patients (P < 0.05). Positioning patients head-up or head-down before pneumoperitoneum did not significantly affect Cst,rs in either group (P = 0.8). Doubling the V(T), but not RR, increased Cst,rs in both groups. Pneumoperitoneum caused large decreases in Cst,rs in both groups (both P < 0.001). During pneumoperitoneum, changing the body position, V(T), or RR did not further affect Cst,rs in either group (P > 0.7). Before pneumoperitoneum, RI,rs was higher in the MO patients compared with the NW patients regardless of body position (P = 0.01). Doubling either RR or V(T) before pneumoperitoneum did not change RI,rs in either group. After pneumoperitoneum, RI,rs increased in both the head-down and head-up positions (P < 0.05), but not in the supine position. Regardless of the conditions studied, alveolar-arterial difference in oxygen tension was always significantly higher in MO patients (P < 0.05). The alveolar-arterial difference in oxygen tension was not affected by body position, pneumoperitoneum, or the mode of ventilation. Arterial oxygenation during laparoscopy was affected only by body weight and could not be improved by increasing either the V(T) or RR. ⋯ Morbid obesity decreases arterial oxygenation and respiratory system compliance. During laparoscopy, arterial oxygenation is affected only by the patient's body weight. Increases in tidal volume or respiratory rate do not improve arterial oxygenation.
-
Anesthesia and analgesia · Jul 2003
Clinical TrialA model to evaluate the pharmacokinetic and pharmacodynamic variables of extended-release products using in vivo tissue microdialysis in humans: bupivacaine-loaded microcapsules.
Biodegradable microcapsules produce an ultra-long duration of local anesthesia. We hypothesized that this duration is caused by the sustained-release of bupivacaine from the microcapsules into the surrounding tissue. Previous studies investigated the pharmacokinetics (PKs) of bupivacaine after release from microcapsules and absorption into the systemic circulation. Microdialysis sampling can determine the PKs of any drug at its site of injection. This study was performed to characterize the PKs of bupivacaine and dexamethasone released from microcapsules at a subcutaneous injection site over a 96-h period in volunteers. Bupivacaine concentrations were compared with clinical variables of local anesthetic blockade. This study demonstrates that bupivacaine is released in a sustained manner from microcapsules, that bupivacaine concentrations increase for 24-34 h after microcapsule injection, and that analgesia parallels the tissue bupivacaine concentration obtained by microdialysis. Analgesia was equally rapid in onset with aqueous and microcapsule bupivacaine (P = 0.23). Analgesia was still present at 78% of microcapsule-injected sites after 96 h, significantly longer than for aqueous bupivacaine (P < 0.001). Mild pruritus was the most common side effect, occurring with 56% of the microcapsule injections. Dexamethasone-containing bupivacaine microcapsules are well tolerated and produce a prolonged duration of skin analgesia. Systemic absorption of bupivacaine produces higher peak plasma levels after aqueous injection than after microcapsule injection, despite the injection of a threefold larger load of bupivacaine in the latter. ⋯ Microcapsules loaded with bupivacaine and dexamethasone and administered by subcutaneous injection produce prolonged cutaneous anesthesia and analgesia. Determination of local tissue pharmacokinetic variables of bupivacaine by microdialysis confirms that the prolonged duration of anesthesia is caused by the extended release characteristics of the microcapsules.
-
Anesthesia and analgesia · Jul 2003
Comparative StudyThe pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model.
The currently marketed propofol formulation has a number of undesirable properties that are in part a function of the lipid emulsion formulation, including pain on injection, serious allergic reactions, and the support of microbial growth. A modified cyclodextrin-based formulation of propofol (sulfobutyl ether-beta-cyclodextrin) has been developed that may mitigate some of these formulation-dependent problems. However, reformulation may alter propofol's pharmacologic behavior. Our aim in this study was to compare the pharmacokinetics and pharmacodynamics of propofol in the currently marketed lipid-based formulation with those of the novel cyclodextrin formulation. We hypothesized that the pharmacokinetics and pharmacodynamics of the propofol in cyclodextrin would be substantially similar to those of the propofol in lipid. Thirty-two isoflurane-anesthetized animals were instrumented with pulmonary artery, arterial, and IV catheters and were randomly assigned to receive either propofol in lipid or propofol in cyclodextrin by continuous infusion. Arterial blood samples for propofol assay were collected. The processed electroencephalogram, heart rate, mean arterial blood pressure, and cardiac output were measured continuously. The propofol formulations were compared by using model-independent analysis techniques. Combined kinetic/dynamic models were also constructed for simulation purposes. There were no significant differences in the pharmacokinetics or pharmacodynamics of the two propofol formulations. The simulations based on the combined pharmacokinetic/pharmacodynamic models confirmed the substantial similarity of the two formulations. The hypothesis that the propofol-in-cyclodextrin formulation would exhibit pharmacokinetic and pharmacodynamic behavior that was substantially similar to the propofol-in-lipid formulation was confirmed. ⋯ A modified cyclodextrin-based formulation of propofol has been developed that may mitigate some of the problems associated with propofol in lipid emulsion. However, reformulation of propofol may change its clinical characteristics. This study in a pig model showed that the novel propofol formulation was substantially similar to the lipid emulsion propofol formulation.